January 09, 2019
1 min read

FDA approves clinical trial for in-home PD system

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Baxter International Inc. recently announced the FDA has indicated that the company may begin a prospective, multicenter clinical trial to test its new on-demand PD generation system that is meant to ease the patient’s experience through use at home, according to a press release from the company.

The clinical trial will assess the effectiveness and safety of the technology, which employs a small water filtration device, turning tap water into dialysis solution to complete therapy sessions, according to the release. This will create a flexible means for individualized patient care.

“We are on a journey to transform how kidney disease is identified, managed and treated, with a focus on improving outcomes for patients,” Laura Angelini, general manager of Baxter’s renal care business, said in the release. “Our on-demand technology is the cornerstone of our innovation pipeline, as we believe the technology will open up new possibilities for therapy delivery while improving the experience for patients today.”